Revance Therapeutics, Inc. (NASDAQ:RVNC) CFO Lauren P. Silvernail sold 11,164 shares of Revance Therapeutics stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $26.67, for a total value of $297,743.88. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Revance Therapeutics, Inc. (NASDAQ RVNC) opened at 26.95 on Tuesday. Revance Therapeutics, Inc. has a 1-year low of $12.35 and a 1-year high of $28.75. The company’s market cap is $830.57 million. The stock has a 50 day moving average price of $25.69 and a 200-day moving average price of $23.53.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $0.03. Revance Therapeutics had a negative return on equity of 55.21% and a negative net margin of 32,936.67%. The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.05 million. During the same quarter in the prior year, the business earned ($0.88) EPS. The business’s revenue for the quarter was up .0% compared to the same quarter last year. Analysts predict that Revance Therapeutics, Inc. will post ($3.61) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Revance Therapeutics, Inc. (RVNC) CFO Lauren P. Silvernail Sells 11,164 Shares of Stock” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/17/revance-therapeutics-inc-rvnc-cfo-lauren-p-silvernail-sells-11164-shares-of-stock.html.

RVNC has been the topic of several recent analyst reports. BidaskClub raised Revance Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Cantor Fitzgerald initiated coverage on Revance Therapeutics in a research note on Thursday, July 20th. They set an “overweight” rating and a $50.00 target price on the stock. Piper Jaffray Companies set a $28.00 target price on Revance Therapeutics and gave the company a “buy” rating in a research note on Wednesday, July 26th. Zacks Investment Research raised Revance Therapeutics from a “sell” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Wednesday, August 9th. Finally, JMP Securities initiated coverage on Revance Therapeutics in a research note on Tuesday, August 22nd. They issued an “outperform” rating and a $34.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $35.20.

A number of large investors have recently bought and sold shares of RVNC. Bank of America Corp DE lifted its holdings in Revance Therapeutics by 29.5% during the 1st quarter. Bank of America Corp DE now owns 7,247 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 1,651 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Revance Therapeutics by 8.1% in the 2nd quarter. Legal & General Group Plc now owns 5,815 shares of the biopharmaceutical company’s stock valued at $152,000 after purchasing an additional 438 shares during the period. Trexquant Investment LP acquired a new position in shares of Revance Therapeutics in the 2nd quarter valued at $231,000. American International Group Inc. lifted its stake in shares of Revance Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 12,590 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 834 shares during the period. Finally, Voya Investment Management LLC acquired a new position in shares of Revance Therapeutics in the 2nd quarter valued at $274,000. 89.32% of the stock is currently owned by hedge funds and other institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Insider Buying and Selling by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Stock Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related stocks with our FREE daily email newsletter.